首页> 外文期刊>Bone marrow transplantation >Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
【24h】

Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.

机译:同种异体移植外周血干细胞后,多发性骨髓瘤,慢性粒细胞白血病和急性粒细胞白血病患者的免疫重建不同。

获取原文
获取原文并翻译 | 示例
           

摘要

In this study we compared the lymphocyte reconstitution in 13 multiple myeloma (MM), nine acute myeloid leukemia (AML) and 10 chronic myeloid leukemia (CML) patients after allogeneic G-CSF-mobilized PBSC transplantation from HLA-identical siblings. Conditioning regimens included standard total body irradiation + cyclophosphamide (CY), or busulphan + CY, whereas VP-16 was added in patients with advanced disease. Overall comparable numbers of mononuclear cells, CD34+ cells and CD3+ T cells were infused in each group. A significantly higher CD3+ T cell number was observed in MM and AML than in CML patients 1 month after transplant. However, MM patients showed a faster and better recovery of CD4+ T cells than both AML and CML patients at 3 months (P = 0.01 and P = 0.01, respectively) and 12 months (P = 0.01 vs AML, while P = NS vs CML) after transplant, and had a CD4:CD8 ratio > 1 with a median CD4+ T cell value > 400/microl 1 year after transplant. Development of acute graft-versus-host disease (GVHD) did not affect CD4:CD8 ratios but patients who experienced acute GVHD > grade I had lower CD4+ and CD8+ T cell numbers at all time points. However, after excluding patients with GVHD > grade I, MM patients still showed a significantly higher CD4+ T cell value than patients with myeloproliferative diseases 1 year after transplant. These findings suggest that although allogeneic PBSC transplantation induces rapid immune reconstitution, different kinetics may occur among patients with hematological malignancies. In particular, the rapid reconstitution of CD4+ T cells in MM patients may contribute to the low transplant-related mortality achieved in this disease.
机译:在这项研究中,我们比较了同种异体G-CSF动员的PBSC移植自HLA相同兄弟姐妹后的13例多发性骨髓瘤(MM),9例急性髓样白血病(AML)和10例慢性髓样白血病(CML)患者的淋巴细胞重构。调理方案包括标准全身照射+环磷酰胺(CY)或Busulphan + CY,而VP-16用于晚期疾病患者。每组中注入了可比较数量的单核细胞,CD34 +细胞和CD3 + T细胞。 MM和AML移植后1个月的CD3 + T细胞数量明显高于CML患者。但是,MM患者在3个月时(分别为P = 0.01和P = 0.01)和12个月时(分别为AML和P = 0.01,NS和CML)显示出比AML和CML患者更快,更好的CD4 + T细胞恢复。 ),并且CD1的CD4:CD8比率> 1,而CD1 + T细胞的中位值在移植后1年大于400 / microl。急性移植物抗宿主病(GVHD)的发展并不影响CD4:CD8的比率,但是经历急性GVHD> I级的患者在所有时间点的CD4 +和CD8 + T细胞数量均较低。但是,在排除GVHD> I级的患者后,MM患者移植后1年仍显示出明显高于骨髓增生性疾病患者的CD4 + T细胞值。这些发现表明,尽管同种异体PBSC移植可诱导快速的免疫重建,但血液系统恶性肿瘤患者可能会发生不同的动力学变化。特别是,MM患者中CD4 + T细胞的快速重建可能有助于降低该疾病中与移植相关的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号